UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events

This study has been completed.
Sponsor:
Collaborators:
European Commission
Imperial College Healthcare NHS Trust
Royal College of Surgeons, Ireland
UMC Utrecht
The George Institute
Public Health Foundation of India
Dr. Reddy's Laboratories Limited
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT01057537
First received: January 26, 2010
Last updated: November 26, 2012
Last verified: November 2012
  Purpose

People with established cardiovascular disease need secondary prevention that addresses multiple risk factors. Complexity & cost confer particularly difficult barriers to uptake of treatment; recovery from a stroke or heart attack typically necessitates multiple drugs for cholesterol, blood pressure and platelet function. A low-cost, fixed-dose, once-daily combination polypill, the Red Heart Pill, has been formulated by Dr Reddy's Laboratories. UMPIRE will evaluate whether provision of this polypill compared with usual medications improves adherence and clinical outcomes among high-risk patients in Europe and India. The results will be used to develop recommendations for equitable access.


Condition Intervention Phase
Cardiovascular Diseases
Drug: polypill
Drug: Usual cardiovascular medications
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Adherence to medication; self-reported current use of antiplatelet, statin and combination (≥ 2) blood pressure lowering therapy [ Time Frame: End of trial follow-up ] [ Designated as safety issue: Yes ]
  • Change in blood pressure [ Time Frame: End of trial follow-up ] [ Designated as safety issue: Yes ]
  • Change in LDL cholesterol [ Time Frame: End of trial follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Self reported current use of antiplatelet, statin and combination (>2) blood pressure lowering therapy [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Reasons for stopping cardiovascular medications [ Time Frame: Throughout trial ] [ Designated as safety issue: Yes ]
  • Serious adverse events [ Time Frame: Throughout trial ] [ Designated as safety issue: Yes ]
  • New onset cardiovascular events [ Time Frame: Throughout trial ] [ Designated as safety issue: Yes ]
  • Participant 'Quality of Life' assessment [ Time Frame: At 12 months and end of trial ] [ Designated as safety issue: No ]
  • Changes in total cholesterol and other lipid fractions (HDL-cholesterol, triglycerides) [ Time Frame: 12 months and end of trial ] [ Designated as safety issue: Yes ]

Enrollment: 2004
Study Start Date: June 2010
Study Completion Date: September 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: polypill
Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
Drug: polypill

The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):

Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.

Other Name: Red Heart Pill
Active Comparator: Usual Care
Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
Drug: Usual cardiovascular medications
Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Other Name: Usual cardiovascular disease prevention medication

Detailed Description:

The UMPIRE trial has been modelled on similar trials running concurrently in Australia and New Zealand. The design is straight forward in making comparisons between cardiovascular preventative therapy delivered as a polypill (the Red Heart Pill) on the one hand, and as separate component multiple tablets (usual care) on the other hand. In both groups (the polypill group and the usual care group,) the GP or managing physician will be able to adjust or add additional medications as appropriate to meet the targets for control of blood pressure, cholesterol and other risk factors as directed by local or national guidelines. The Primary endpoint - adherence to prescribed cardiovascular preventative medication at the end of the trial follow-up - will be evaluated by self reported use of anti-platelet, statin and blood pressure lowering therapy. This evaluation will be supported by the recording of blood pressure and cholesterol levels, and measuring the differences between the two groups at the end of the trial. Treatment allocation is open label - both investigator and subject will know which arm of the study they are on. Patients will be identified and recruited from GP surgeries or hospital clinics, and also via local advertisement. Recruitment into the study is planned to start in Summer 2010 with a 12 month recruitment phase. Recruited subjects will spend between 12 - 30 months (average 18 months) being followed up. The target study population is 1000 patients in European at sites in London, Dublin and Utrecht; and 1000 subjects in India at approximately 30 sites. Subjects will be randomly allocated to receive either the "polypill" or "usual care". If allocated to the polypill group, the study investigator will decide on the version of polypill to be prescribed, and adjust any current medications as necessary. If the subject is in the "usual care" group, they will be seen as needed by their usual doctor between study visits, and continue on their current medicines. Participants will have at least 5 study visits, but no more than 8 study visits, and these visits include registration, randomisation and follow-up visits at 1 month, 6 months, and 12 months, and depending on when the subject is recruited to the study, study visits at 18 and 24 months/end of trial visit. A substudy, PESCA (Protocol ID CR01656, NCT01326676), will be performed in the European participants to assess whether the polypill reduces progression of atherosclerosis. This will be assessed by measuring carotid intima-medial thickness and central systolic blood pressure using the PulseCor device. A second substudy, INPUT, is a process evaluation involving qualitative interviews of a sample of health practitioners and trial participants at the end of the trial (summer 2012) in London and India.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults (≥ 18 years)
  • The participant is able to give informed consent.
  • Established atherothrombotic cardiovascular disease (CVD) or high cardiovascular risk, of for individuals without established cardiovascular disease, a calculated 5 year CVD risk of 15% or greater (calculated using the 1991 Anderson Framingham risk equation with adjustments as defined by the New Zealand Guidelines Group recommendations)
  • The trial Investigator considers that each of the polypill components are indicated
  • The trial Investigator is unsure as to whether a polypill-based strategy or usual care is better.

Exclusion Criteria:

  • Contraindication to any of the components of the polypill (e.g. known intolerance to aspirin, statins, or ACE inhibitors,pregnancy or likely to become pregnant during the treatment period).
  • The treating doctor considers that changing a participant's cardiovascular medications would put the participant at risk (e.g. symptomatic heart failure, high dose βblocker required to manage angina or for rate control in atrial fibrillation,accelerated hypertension, severe renal insufficiency, a history of severe resistant hypertension)
  • Known situation where medication regimen might be altered for a significant length of time, e.g. current acute cardiovascular event, planned coronary bypass graft operation.
  • Unlikely to complete the trial (e.g. lifethreatening condition other than cardiovascular disease) or adhere to the trial procedures or attend study visits (e.g. major psychiatric condition, dementia).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01057537

Locations
Australia, New South Wales
George Institute Australia
Sydney, New South Wales, Australia, 2050
India
George Institute for International Health - India
Hyderabad, India, 500033
Public Health Foundation of India
New Dehli, India, 110049
Centre for Chronic Disease Control
New Delhi, India, 110016
Ireland
Royal College of Surgeons in Ireland Research Institute
Dublin, Ireland, Dublin 9
Netherlands
University Medical Center Utrecht
Utrecht, Heidelberglaan 100, Netherlands, 3584 CX
United Kingdom
Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College London
Paddington, London, United Kingdom, W2 1LA
Sponsors and Collaborators
Imperial College London
European Commission
Imperial College Healthcare NHS Trust
Royal College of Surgeons, Ireland
UMC Utrecht
The George Institute
Public Health Foundation of India
Dr. Reddy's Laboratories Limited
Investigators
Study Director: Simon A McG Thom, MD, FRCP Imperial College London
Principal Investigator: Neil Poulter Imperial College London
Principal Investigator: Anushka Patel The George Institute, India
Principal Investigator: Dorairaj Prabhakaran Centre for Chronic Disease Control
Principal Investigator: Michiel Bots UMC Utrecht
Principal Investigator: Diederick Grobbee UMC Utrecht
Principal Investigator: Alice Stanton Royal College of Surgeons in Ireland
Principal Investigator: Anthony Rodgers The George Institute, Australia
Principal Investigator: Raghu Cidambi Dr. Reddy's Laboratories Limited
Principal Investigator: K Srinath Reddy Public Health Foundation of India
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01057537     History of Changes
Other Study ID Numbers: 241849, 2009-016278-34
Study First Received: January 26, 2010
Last Updated: November 26, 2012
Health Authority: United Kngdom: Medicines and Healthcare products Regulatory Agency (MHRA)
Ireland: Irish Medicines Board (IMB)
The Netherlands: Dutch Healthcare Inspectorate (CCMO)
India: Drugs Controller General, India (DCGI)

Keywords provided by Imperial College London:
Polypill
Red Heart Pill
Cardiovascular disease
Adherence
Secondary prevention

Additional relevant MeSH terms:
Cardiovascular Diseases
Contraceptives, Oral
Cardiovascular Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on September 30, 2014